Alswat Khalid A, Fallatah Hind I, Al-Judaibi Bandar, Elsiesy Hussien A, Al-Hamoudi Waleed K, Qutub Adel N, Alturaify Naif, Al-Osaimi Abdullah
Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. E-mail.
Saudi Med J. 2019 Jun;40(6):531-540. doi: 10.15537/smj.2019.6.23980.
Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.
非酒精性脂肪性肝病（NAFLD）是一项重大的国内外健康负担。它是全球最常见的肝脏疾病之一，也是许多发达国家肝酶异常的最常见原因。非酒精性脂肪性肝病还是隐源性肝硬化的重要病因及肝移植的第二大主要原因。它通常与代谢综合征相关。非酒精性脂肪性肝炎（NASH）是NAFLD的进展性表型。尽管非侵入性检查手段表现出良好前景，但肝活检仍是NASH诊断的金标准检查。几十年来，许多药物已进入2期和3期研究；然而，迄今为止尚无获批的治疗方法。尽管全球NAFLD发病率令人担忧，但尚无基于当地社区的NAFLD患病率研究或关于其管理的当地实践指南；本专家综述旨在填补这一空白。
